Evaxion to Present New Preclinical Data for AI-Designed CMV Vaccine Candidate

Evaxion’s EVX-V1 vaccine candidate uses an AI-driven, multi-antigen approach to target cytomegalovirus (CMV) — a leading cause of congenital hearing loss and disability in newborns for which no approved vaccine yet exists. Evaxion A/S will present new preclinical data for its cytomegalovirus (CMV) vaccine candidate, EVX-V1, at the International Herpesvirus Workshop (IHW) 2026, taking place July 11–15 in Montreal,...

No actionable change — this is preclinical (animal/lab-stage) data presented at a conference; it has no bearing on current clinical audiology practice.

CMV is the leading infectious cause of congenital hearing loss, and a successful vaccine could one day dramatically reduce the number of children born with hearing impairment.

1. 01Evaxion's EVX-V1 is an AI-designed multi-antigen vaccine candidate targeting cytomegalovirus (CMV).
2. 02CMV is the leading non-genetic cause of congenital (present-at-birth) hearing loss in newborns.
3. 03No CMV vaccine is currently approved anywhere in the world.
4. 04Data being presented are preclinical — from lab or animal studies, not human trials.
5. 05The AI-based design approach aims to identify multiple viral targets to potentially improve immune response.